http://orcid.org/0000-0002-1068-4261
References
- Eksterowicz J, Rock DA, Rock BM, et al. (2014). Characterization of the active site properties of CYP4F12. Drug Metab Dispos 42:1698–707
- Hashizume T, Imaoka S, Mise M, et al. (2002). Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298–304
- Honig PK, Woosley RL, Zamani K, et al. (1992). Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52:231–18
- Honig PK, Wortham DC, Zamani K, et al. (1993). Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 269:1513–18
- Jones BC, Hyland R, Ackland M, et al. (1998). Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. Drug Metab Dispos 26:875–82
- Jurima-Romet M, Crawford K, Cyr T, Inaba T. (1994). Terfenadine metabolism in human liver in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22:849–57
- Lee CA, Neul D, Clouser-Roche A, et al. (2010). Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos 38:347–56
- Nishimuta H, Sato K, Mizuki Y, et al. (2011). Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans. Drug Metab Pharmacokinet 26:300–6
- Rendic S, Guengerich FP. (2012). Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol 25:1316–83
- Uehara S, Inoue T, Utoh M, et al. (2016a). Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol, and midazolam, in common marmosets (Callithrix jacchus). Xenobiotica 46:163–8
- Uehara S, Uno Y, Hagihira Y, et al. (2015). Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol, and dextromethorphan. Xenobiotica 45:757–65
- Uehara S, Uno Y, Inoue T, et al. (2016b). Marmoset cytochrome P450 2J2 mainly expressed in small intestines and livers effectively metabolizes human P450 2J2 probe substrates, astemizole and terfenadine. Xenobiotica 46:977–85
- Uehara S, Uno Y, Ishii S, et al. (2017). Marmoset cytochrome P450 4A11, a novel arachidonic acid and lauric acid ω-hydroxylase expressed in liver and kidney tissues. Xenobiotica. [Epub ahead of print]. doi: 10.1080/00498254.2016.1206673
- Uehara S, Uno Y, Yuki Y, et al. (2016c). A new marmoset P450 4F12 enzyme expressed in small intestines and livers efficiently metabolizes an anti-histaminic drug ebastine. Drug Metab Dispos 44:833–41
- Uno Y, Uehara S, Yamazaki H. (2016). Utility of non-human primates in drug development: comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes. Biochem Pharmacol 121:1–7
- Wang MZ, Saulter JY, Usuki E, et al. (2006). CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab Dispos 34:1985–94
- Yun CH, Okerholm RA, Guengerich FP. (1993). Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 21:1–7